Q-omics provides the consensus-scored ARMC4P1 profile across patient tissues and cancer cell-line models. ARMC4P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ARMC4P1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ARMC4P1 RNA expression shows 11,511 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where ARMC4P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMC4P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMC4P1 survival associations across molecular data types. ARMC4P1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMC4P1 RNA expression–survival associations across cancer types. High ARMC4P1 expression shows unfavorable associations in COAD, UVM, CHOL, LGG and BRCA, but favorable associations in KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for ARMC4P1 RNA expression.
This table summarizes ARMC4P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ARMC4P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMC4P1 shows lower tumor expression in KIRC, THCA, KIRP, UCEC and PRAD and higher tumor expression in LIHC. The KIRC box plot shows higher ARMC4P1 RNA expression in normal versus tumor tissue (log2 FC = −1.081, t-test p < 0.001).
This table shows molecular features associated with ARMC4P1 in patient tissues and cancer cell lines. In patient samples, ARMC4P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
